A chest wall sarcoma, a recurrence 8 years after index excision: a case report

Catherine Kilada; David Egbo; Christina Montesano; Tereque Raeburn; Martine A. Louis; Nageswara Mandava

doi:10.18203/2349-2902.isj20252289

Authors

Catherine Kilada Department of Surgery, Flushing Hospital Medical Center, Queens, NY, USA
David Egbo Ross University School of Medicine, Bridgetown, St. Michael, Barbados
Christina Montesano New York Institute of Technology College of Osteopathic Medicine, Old Westbury, NY, USA
Tereque Raeburn St. George’s University, True Blue, St. George, Grenada
Martine A. Louis Department of Surgery, Flushing Hospital Medical Center, Queens, NY, USA
Nageswara Mandava Department of Surgery, Flushing Hospital Medical Center, Queens, NY, USA

DOI:

https://doi.org/10.18203/2349-2902.isj20252289

Keywords:

Sarcoma, Recurrent soft tissue sarcoma, Chest wall tumor, Fibromyxoid sarcoma

Abstract

Soft tissue sarcomas (STS) occur in 2-5 patients per 100,000 people, as a rare heterogeneous group of tumors arising in connective tissues, embryologically derived from mesenchyme. These tumors comprise <1% of all neoplasms with a 4:1 male preponderance. Prognosis depends on size, grade, depth and metastasis. Even in STS classified as low-grade, the risk of local recurrence requiring further intervention remains high, therefore emphasizing the importance of long-term follow-up. While nodal metastasis is rare, the tumor immediately becomes stage III when this occurs, regardless of size or depth. More than 50 subtypes exist and originate from cartilage, muscle, blood vessels, nerves, fat, tendons and deep skin tissues. Low-grade fibromyxoid sarcoma (LGFMS), one rare subtype with a relatively benign histologic appearance, has a high recurrence rate, late metastatic spread, and chemotherapy and radiotherapy insensitivity. We present the case of a 57-year-old male with a right chest wall mass diagnosed as a recurrent low-grade fibromyxoid sarcoma (LGFMS) 8 years after index excision. We emphasize the importance of early detection and management given the value of early surgical intervention due to the limited response of adjuvant therapy in this low-grade yet aggressive tumor.

Metrics

Metrics Loading ...

References

Bleloch JS, Ballim RD, Kimani S, Parkes J, Panieri E, Willmer T, et al. Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol. 2017;9(10):637-59. DOI: https://doi.org/10.1177/1758834017728927

Muehlhofer HML, Schlossmacher B, Lenze U, Lenze F, Burgkart R, Gersing AS, et al. Oncological Outcome and Prognostic Factors of Surgery for Soft Tissue Sarcoma After Neoadjuvant or Adjuvant Radiation Therapy: A Retrospective Analysis over 15 Years. Anticancer Res. 2021;41(1):359-68. DOI: https://doi.org/10.21873/anticanres.14784

Gómez J, Tsagozis P. Multidisciplinary treatment of soft tissue sarcomas: An update. World J Clin Oncol. 2020;11(4):180-9. DOI: https://doi.org/10.5306/wjco.v11.i4.180

O’Sullivan B, Davis A, Turcotte R, Bell R, Wunder J, Catton C, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2004;22(14):9007. DOI: https://doi.org/10.1200/jco.2004.22.90140.9007

Khamashta N, Dalal A, Alashwas M, Idkedek M, Abu-Akar F. Case report and review of literature: Resection of a huge mediastinal low-grade fibromyxoid sarcoma with neck, axillary, and lung involvement. Front Surg. 2022;9:988881. DOI: https://doi.org/10.3389/fsurg.2022.988881

Vodanovich DA, Choong PFM. Soft-tissue Sarcomas. Indian J Orthop. 2018;52(1):35-44. DOI: https://doi.org/10.4103/ortho.IJOrtho_220_17

Von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, et al. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(7):815-33. DOI: https://doi.org/10.6004/jnccn.2022.0035

Chamberlain F, Engelmann B, Al-Muderis O, Messiou C, Thway K, Miah A, Zaidi S, Constantinidou A, Benson C, Gennatas S, Jones RL. Low-grade fibromyxoid sarcoma: treatment outcomes and efficacy of chemotherapy. In Vivo. 2020;34(1):239-45. DOI: https://doi.org/10.21873/invivo.11766

Mohamed M, Fisher C, Thway K. Low-grade fibromyxoid sarcoma: Clinical, morphologic and genetic features. Ann Diagnost Pathol. 2017;28:60-7. DOI: https://doi.org/10.1016/j.anndiagpath.2017.04.001

Farid M, Ngeow J. Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review. Oncologist. 2016;21(8):1002-13. DOI: https://doi.org/10.1634/theoncologist.2016-0079

Ronen S, Ko JS, Rubin BP, Kilpatrick SE, Wang WL, Lazar AJ, et al. Superficial low-grade fibromyxoid sarcoma. J Cutan Pathol. 2023;50(2):147-54. DOI: https://doi.org/10.1111/cup.14325

Cowan ML, Thompson LD, Leon ME, Bishop JA. Low-Grade Fibromyxoid Sarcoma of the Head and Neck: A Clinicopathologic Series and Review of the Literature. Head Neck Pathol. 2016;10(2):161-6. DOI: https://doi.org/10.1007/s12105-015-0647-8

Lee BJ, Park WS, Jin JM, Ha CW, Lee SH. Low grade fibromyxoid sarcoma in thigh. Clin Orthop Surg. 2009;1(4):240-3. DOI: https://doi.org/10.4055/cios.2009.1.4.240

Li M, Chen H, Shi D, Chen M, Zhang Z, Zhang H. Low-grade fibromyxoid sarcoma: a clinicopathologic and molecular study of 10 genetically confirmed cases. Int J Clin Exp Pathol. 2018;11(12):5860-8.

Liu KT, Chang YC, Lin YC, Chang JL. Unusual extrahepatic metastatic site of hepatocellular carcinoma with post-therapy disseminating metastases presenting as a primary soft tissue sarcoma: case report. Ann Med Surg (Lond). 2024;86(9):5501-8. DOI: https://doi.org/10.1097/MS9.0000000000002307

Kimura T. Soft Tissue Squamous Cell Carcinoma in Chest Wall with an Incomplete Border Sign. J Med Cases. 2011;jmc115w. DOI: https://doi.org/10.4021/jmc115w

Griffo S, Stassano P, De Luca G, Di Tommaso L, Monaco M, Spiezia S. Intramuscular hemangioma of the chest wall: An unusual tumor. J Thorac Cardiovasc Surg. 2007;134(5):1368-9. DOI: https://doi.org/10.1016/j.jtcvs.2007.07.017

Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, et al. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemother Pharmacol. 2016;77(1):133-46. DOI: https://doi.org/10.1007/s00280-015-2809-5

Berger‐Richardson D, Swallow CJ. Needle tract seeding after percutaneous biopsy of sarcoma: Risk/benefit considerations. Cancer. 2017;123(4):560-7. DOI: https://doi.org/10.1002/cncr.30370

Gamboa AC, Gronchi A, Cardona K. Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine. CA A Cancer J Clinicians. 2020;70(3):200-29. DOI: https://doi.org/10.3322/caac.21605

Hassan U, Saeed SM Sr, Mushtaq S, Hussain M, Hameed M. The Expression of Mucin-4 (MUC4) in Sarcomas Apart From Sclerosing Epithelioid Fibrosarcoma and Low-Grade Fibromyxoid Sarcoma. Cureus. 2023;15(11):e49546. DOI: https://doi.org/10.7759/cureus.49546

Doyle LA, Möller E, Cin PD, Fletcher CDM, Mertens F, Hornick JL. MUC4 Is a Highly Sensitive and Specific Marker for Low-grade Fibromyxoid Sarcoma. Am J Surg Pathol. 2011;35(5):733-41. DOI: https://doi.org/10.1097/PAS.0b013e318210c268

Sugiura H, Tsukushi S, Yoshida M, Nishida Y. What Is the Success of Repeat Surgical Treatment of a Local Recurrence After Initial Wide Resection of Soft Tissue Sarcomas? Clin Orthop Relat Res. 2018;476(9):1791-800. DOI: https://doi.org/10.1007/s11999.0000000000000158

Nunes Pombo J, Nixon Martins A, Paias Gouveia C, et al. Rare case of low-grade fibromyxoid sarcoma of the thoracic wall with complete sternum reconstruction. Case Rep Plast Surg Hand Surg. 2022;9(1):126-130. DOI: https://doi.org/10.1080/23320885.2022.2064290

Cecchetto G, Bisogno G, De Corti F, Nawojowska Á, Mendes S, Cabral D, et al. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: The experience of the Italian cooperative group studies. Cancer. 2007;110(11):2561-7. DOI: https://doi.org/10.1002/cncr.23079

Farzaliyev F, Steinau HU, Ring A, Hamacher R, Thiel T, Lauer H, et al. Outcome of Surgery as Part of Palliative Care of Patients with Symptomatic Advanced or Metastatic Extra-Abdominal High-Grade Soft Tissue Sarcoma. Palliat Med Rep. 2023;3(1):64-70. DOI: https://doi.org/10.1089/pmr.2022.0063

Spalato-Ceruso M, Ghazzi NE, Italiano A. New strategies in soft tissue sarcoma treatment. J Hematol Oncol. 2024;17(1):76. DOI: https://doi.org/10.1186/s13045-024-01580-3

Tian Z, Yao W. Chemotherapeutic drugs for soft tissue sarcomas: a review. Front Pharmacol. 2023;14:1199292. DOI: https://doi.org/10.3389/fphar.2023.1199292

Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016;122(19):2952-60. DOI: https://doi.org/10.1002/cncr.30191

Lin JS, Coleman L, Voskuil RT, Malik A, Mayerson JL, Scharschmidt TJ. Local recurrence rates of superficial versus deep soft tissue sarcoma. Arch Orthop Trauma Surg. 2024;144(7):2967-73. DOI: https://doi.org/10.1007/s00402-024-05326-1

Zhang X, Qiu Y, Zhang J, Chen Z, Yang Q, Huang W, et al. An elderly low-grade fibromyxoid sarcoma patient with early postoperative recurrences and metastases: a case report and literature review. Front Med. 2024;11:1172746. DOI: https://doi.org/10.3389/fmed.2024.1172746

Lee DW, Kim HS, Han I. Actual long-term survival after resection of stage III soft tissue sarcoma. BMC Cancer. 2021;21(1):21. DOI: https://doi.org/10.1186/s12885-020-07730-3